Status:
UNKNOWN
High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Endoscopy
Peptic Ulcer
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
The study was designed to evaluate the efficacy an adjuvant use of standard dose or high dose of proton pump inhibitor after combined endoscopic hemostasis therapy.
Detailed Description
Acute peptic ulcer bleeding remains the most common cause of acute upper gastrointestinal bleeding. Endoscopy serves as a tool for initial diagnosis and triage and also a tool for immediate hemostasis...
Eligibility Criteria
Inclusion
- adults aged above 16 years old with acute nonvariceal upper gastrointestinal bleeding
- read, agree to attend the study, and signed informed consent indicated to receive esophagogastroduodenoscopy(EGD)
- peptic ulcers with high risk lesions (active bleeding: spurting, oozing peptic ulcers. Ulcers with NBVV: nonbleeding visible vessel)
Exclusion
- unable to receive EGD (unable to open mouth, upper gastrointestinal obstruction)
- bleeding tendency (platelet \< 50x109/L, prothrombin time INR \>2, ongoing use of heparin or coumadin)
- gastric malignancy
- myocardial infarction within recent one week
- recent cerebrovascular event within recent one week
- pregnancy
- refuse to attend the study
- known allergy history to epinephrine or pantoprazole
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00709046
Start Date
January 1 2008
Last Update
January 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan